文献速递性腺与生殖内分泌垂体与肾上腺疾病

重组人促卵泡激素α联合人绒毛膜促性腺激素治疗青少年男性低促性腺激素性性腺功能减退症

Corifollitropin Alfa Combined With Human Chorionic Gonadotropin in Adolescent Boys With Hypogonadotropic Hypogonadism.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

这项64周、多中心、开放标签、单组研究评估了重组人促卵泡激素α(CFA)联合hCG对14至18岁以下低促性腺激素性性腺功能减退症(HH)青少年男性的疗效与安全性。17名受试者先接受12周CFA单独引导,随后52周CFA联合hCG治疗。结果显示睾丸体积几何均值较基线增加9.43倍(95%CI 7.44-11.97),激素、Tanner分期和生长速度变化与青春期启动和进展一致,治疗总体耐受良好,未出现抗CFA抗体。

要点

  • CFA联合hCG治疗64周后睾丸体积几何均值较基线增加9.43倍(95%CI 7.44-11.97)。
  • 激素、Tanner分期和生长速度变化与青春期启动和进展一致。
  • 治疗总体耐受良好,无受试者产生抗CFA抗体。

核心结论

  • 对HH青少年男性先单用CFA 12周、再联合hCG 52周,可诱导睾丸生长并伴随青春期进展、睾酮升高和青春期生长突增。

研究设计与样本

  • 64周、多中心、开放标签、单组研究,纳入17名14岁至未满18岁的HH青少年男性。
  • 先接受12周CFA引导期(体重≤60 kg者100 μg,体重>60 kg者150 μg,每2周皮下注射一次),随后进入52周CFA(每2周一次)联合hCG(每周两次皮下注射,剂量在500 IU至5000 IU之间调整以维持总睾酮和雌二醇在方案规定范围内)的联合治疗期。
  • 主要疗效终点为超声测量的左右睾丸体积之和(TV)较基线的变化。

主要发现

  • 治疗64周后,TV较基线的几何均值倍数增加为9.43(95%CI 7.44-11.97),第64周较基线变化的算术均值为13.0 mL。
  • 激素、Tanner分期和生长速度变化与青春期启动和进展一致。
  • 治疗总体耐受良好,无受试者产生抗CFA抗体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Adolescent males with hypogonadotropic hypogonadism (HH) have traditionally been treated with exogenous testosterone (T) or human chorionic gonadotropin (hCG) to produce virilization; however, those modalities do not result in growth of the testes and may promote premature maturation and terminal differentiation of Sertoli cells prior to their proliferation, which may impact future fertility. Another option is to use gonadotropins in those individuals to induce testicular growth, proliferation and maturation of Sertoli cells, and production of endogenous T with consequent virilization. OBJECTIVE: We examined the efficacy and safety of corifollitropin alfa (CFA) combined with hCG for the induction of testicular growth and pubertal development in adolescent boys with HH. METHODS: This was a 64-week, multicenter, open-label, single-group study of CFA in adolescent boys, aged 14 to younger than 18 years, with HH. Seventeen participants initiated a 12-week priming period with CFA (100 μg if weight ≤ 60 kg, or 150 μg if weight > 60 kg) given subcutaneously once every 2 weeks, after which they entered a 52-week combined treatment period with CFA, once every 2 weeks, and subcutaneous hCG, twice-weekly (hCG dose adjusted between 500 IU and 5000 IU to keep total T and estradiol levels within protocol-specified ranges). The primary efficacy end point was change from baseline in testicular volume (TV), measured as the sum of volumes of left and right testes by ultrasound. RESULTS: After 64 weeks of therapy with CFA/CFA combined with hCG, geometric mean fold increase from baseline in TV was 9.43 (95% CI, 7.44-11.97) (arithmetic mean of change from baseline at week 64, 13.0 mL). Hormonal, Tanner stage, and growth velocity changes were consistent with initiation and progression of puberty. Treatment was generally well tolerated. No participant developed anti-CFA antibodies. CONCLUSION: Treatment of adolescent boys with HH with CFA alone for 12 weeks followed by CFA combined with hCG for 52 weeks induced testicular growth accompanied by pubertal progression, increased T, and a pubertal growth spurt (EudraCT: 2015-001878-18).

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Shankar RR, Shah S, Joeng HK, et al. Corifollitropin Alfa Combined With Human Chorionic Gonadotropin in Adolescent Boys With Hypogonadotropic Hypogonadism. J Clin Endocrinol Metab. 2022. PMID: 35275602. doi:10.1210/clinem/dgac145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。